Naja Atra Cardiotoxin 3 Elicits Autophagy and Apoptosis in U937 Human Leukemia Cells Through the Ca2+/PP2A/AMPK Axis

Total Page:16

File Type:pdf, Size:1020Kb

Naja Atra Cardiotoxin 3 Elicits Autophagy and Apoptosis in U937 Human Leukemia Cells Through the Ca2+/PP2A/AMPK Axis toxins Article Naja atra Cardiotoxin 3 Elicits Autophagy and Apoptosis in U937 Human Leukemia Cells through the Ca2+/PP2A/AMPK Axis Jing-Ting Chiou 1, Yi-Jun Shi 1, Liang-Jun Wang 1, Chia-Hui Huang 1, Yuan-Chin Lee 1 and Long-Sen Chang 1,2,* 1 Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, Taiwan 2 Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan * Correspondence: [email protected]; Tel.: +886-7-5252-000-5813 Received: 23 August 2019; Accepted: 10 September 2019; Published: 12 September 2019 Abstract: Cardiotoxins (CTXs) are suggested to exert their cytotoxicity through cell membrane damage. Other studies show that penetration of CTXs into cells elicits mitochondrial fragmentation or lysosome disruption, leading to cell death. Considering the role of AMPK-activated protein kinase (AMPK) in mitochondrial biogenesis and lysosomal biogenesis, we aimed to investigate whether the AMPK-mediated pathway modulated Naja atra (Taiwan cobra) CTX3 cytotoxicity in U937 human leukemia cells. Our results showed that CTX3 induced autophagy and apoptosis in U937 cells, whereas autophagic inhibitors suppressed CTX3-induced apoptosis. CTX3 treatment elicited Ca2+-dependent degradation of the protein phosphatase 2A (PP2A) catalytic subunit (PP2Acα) and phosphorylation of AMPKα. Overexpression of PP2Acα mitigated the CTX3-induced AMPKα phosphorylation. CTX3-induced autophagy was via AMPK-mediated suppression of the Akt/mTOR pathway. Removal of Ca2+ or suppression of AMPKα phosphorylation inhibited the CTX3-induced cell death. CTX3 was unable to induce autophagy and apoptosis in U937 cells expressing constitutively active Akt. Met-modified CTX3 retained its membrane-perturbing activity, however, it did not induce AMPK activation and death of U937 cells. These results conclusively indicate that CTX3 induces autophagy and apoptosis in U937 cells via the Ca2+/PP2A/AMPK axis, and suggest that the membrane-perturbing activity of CTX3 is not crucial for the cell death signaling pathway induction. Keywords: cardiotoxin; Ca2+; PP2A; AMPK; autophagy; apoptosis Key Contribution: The cytotoxicity of N. atra CTX3 on U937 cells is related to the Ca2+/PP2A/AMPK axis-elicited autophagy and apoptosis; Our data suggest a dissociation of CTX3-induced death signaling from its effect on cell membrane damage. 1. Introduction Cobra cardiotoxins (CTXs) show a wide range of biological activities including hemolysis, cardiotoxicity, and disruption of muscular integrity [1–3]. Moreover, accumulated evidence has shown that CTXs induce apoptosis in cancer cells through the mitochondria-mediated apoptotic pathway, lysosome-mediated death pathway, or membrane-damaging effects [4–8]. It is widely believed that the plasma membrane is a target of CTXs, but the membrane pore formed by CTXs may have a limited lifetime on the cell surface due to membrane reorganization [9]. Therefore, some studies indicate that the cytotoxicity of CTXs is related to their capability of cell penetration [4,7,10,11]. The internalized CTXs are suggested to elicit mitochondrial fragmentation [10,11] or lysosome disruption [4,7], and thereby induce the death of the myoblast cells, primary cortical neurons, or cancer cells. Notably, Langone Toxins 2019, 11, 527; doi:10.3390/toxins11090527 www.mdpi.com/journal/toxins Toxins 2019, 11, x FOR PEER REVIEW 2 of 12 Toxinslysosome2019, 11 disruption, 527 [4,7], and thereby induce the death of the myoblast cells, primary cortical2 of 12 neurons, or cancer cells. Notably, Langone et al. [12] found that activated AMPK can attenuate the etcytotoxicity al. [12] found of Naja that activatedpallida CTX AMPK on myoblast can attenuate cells. AMPK the cytotoxicity has been ofdemonstratedNaja pallida CTX to be on involved myoblast in cells.mitochondrial AMPK has biogenesis been demonstrated [13,14] and to belysosomal involved biogenesis in mitochondrial [15]. Some biogenesis studies [13 have,14] and revealed lysosomal that biogenesisAMPK acts [15 as]. a Sometumor studies suppressor have or revealed oncogene that in AMPKdifferent acts cancer as a tumorcells [16]. suppressor Other studies or oncogene indicate inthat di ffAMPK-mediatederent cancer cells signaling [16]. Other elicits studies death indicate in cancer that AMPK-mediatedcells via autophagy signaling and/or elicitsapoptosis death [17]. in cancerTherefore, cells it via is autophagyintriguing to and explore/or apoptosis the role [17 of]. the Therefore, AMPK-mediated it is intriguing pathway to explore in the thecytotoxicity role of the of AMPK-mediatedCTXs. Prior studies pathway have inshown the cytotoxicity that human of myeloid CTXs. Prior leukemia studies cells have are shown highly that susceptible human myeloid to the leukemiacytotoxicity cells of are CTXs highly [4,7,18]. susceptible Therefore, to the we cytotoxicity investigated of whether CTXs [4 ,7the,18 AMPK-associated]. Therefore, we investigated pathway is whetheran important the AMPK-associated mediator in N. atra pathway CTX3-induced is an important death ofmediator human leukemia in N. atra U937CTX3-induced cells. death of human leukemia U937 cells. 2. Results 2. ResultsTreatment with CTX3 reduced the U937 survival of cells in a concentration- and time-dependent mannerTreatment with an with IC50 CTX3 value reduced of approximately the U937survival 150 nM for of cells a 4-h in treatment a concentration- (Figure and1A). time-dependent Hence, we used mannerthis dose with of CTX3 an IC 50tovalue study of the approximately mechanism of 150 itsnM cytotoxicity. for a 4-htreatment CTX3 treatment (Figure 1increasedA). Hence, the we number used thisof annexin dose of CTX3V-FITC to staining study the U937 mechanism cells (Figure of its 1B). cytotoxicity. In line with CTX3 this, treatment the CTX-treated increased cells the numbershowed ofdegradation annexin V-FITC of procaspase-3 staining U937 and PARP cells (Figure (Figure1 B).1C), In whereas line with the this, caspase the CTX-treated inhibitors inhibited cells showed the cell degradationdeath induced of procaspase-3by CTX3 (Figure and PARP1D). These (Figure results1C), whereas indicated the that caspase CTX3 inhibitors induces apoptosis inhibited thein U937 cell deathcells. induced by CTX3 (Figure1D). These results indicated that CTX3 induces apoptosis in U937 cells. Figure 1. Cobra cardiotoxin (CTX)3 induced apoptotic death of U937 cells. (A)Effect of CTX3 on the viabilityFigure 1. of Cobra U937 cells.cardiotoxin Cells were (CTX)3 incubated induced with apoptotic indicated death CTX3 of U937 concentrations cells. (A) Effect for 4 h.of (Inset)CTX3 on U937 the cellsviability were of treated U937 withcells. 150Cells nM were CTX3 incubated for indicated with indicated time periods. CTX3 Cell concentrations viability was for determined 4 h. (Inset) using U937 methlythiazolyldiphenyl-tetrazoliumcells were treated with 150 nM CTX3 bromide for indicated (MTT) time assay. periods. Results Cell are viability expressed was as determined the percentage using of cellmethlythiazolyldiphenyl-tetrazolium survival relative to the control. Each bromide value is the(MTT) mean assay.SD Results of three are independent expressed experimentsas the percentage with ± triplicateof cell survival measurements; relative to (B the) Flow control. cytometry Each va analyseslue is the of mean±SD annexin V-PI of three double independent staining CTX3-treated experiments cells.with U937triplicate cells measurements; were incubated (B with) Flow 150 cytometry nM CTX3 analyses for 4 h. Onof annexin the flow V-PI cytometric double scatterstaining graphs, CTX3- thetreated left lowercells. U937 quadrant cells representswere incubated remaining with 150 live nM cells. CTX3 The for right 4 h. lower On the quadrant flow cytometric represents scatter the populationgraphs, the ofleft early lower apoptotic quadrant cells. represents The right remaining upper quadrantlive cells. representsThe right lower the accumulation quadrant represents of late apoptoticthe population cells; (ofC) early Western apoptotic blot analyses cells. The of right procaspase-3 upper quadrant and poly(ADP-ribose) represents the accumulation polymerase (PARP) of late degradationapoptotic cells; in CTX3-treated (C) Western blot cells. analyses U937 cells of procaspase-3 were incubated and with poly(ADP-ribose) 150 nM CTX3 for polymerase 4 h; (D) Viability (PARP) ofdegradation CTX3-treated in CTX3-treated cells was restored cells. by U937 pretreatment cells were with incubated caspase with inhibitors. 150 nM U937CTX3 cells for 4 were h; (D pretreated) Viability withof CTX3-treated 10 µM Z-VAD-FMK cells was (pan-caspase restored by inhibitor)pretreatment or Z-DEVD-FMK with caspase inhibitors. (caspase-3 inhibitor)U937 cells for were 1 h, pretreated and then incubatedwith 10 μM with Z-VAD-FMK 150 nM CTX3 (pan-caspase for 4 h. Each inhibitor) value is or the Z-DE meanVD-FMKSD of (caspase-3 three independent inhibitor) experiments for 1 h, and ± with triplicate measurements (* p < 0.05). Toxins 2019, 11, x FOR PEER REVIEW 3 of 12 then incubated with 150 nM CTX3 for 4 h. Each value is the mean ± SD of three independent Toxins 2019experiments, 11, 527 with triplicate measurements (* p < 0.05). 3 of 12 To examine whether CTX3-induced apoptosis is related to mitochondrial dysfunction, the To examine whether CTX3-induced apoptosis is related to mitochondrial dysfunction, mitochondrial membrane potential (ΔΨm) of CTX3-treated cells was thus measured using TMRM the mitochondrial membrane potential (DYm) of CTX3-treated
Recommended publications
  • Anti-Inflammatory and Immune Regulatory Actions of Naja Naja
    toxins Review Anti-Inflammatory and Immune Regulatory Actions of Naja naja atra Venom Shu-Zhi Wang 1,2 and Zheng-Hong Qin 3,* 1 Institute of Pharmacy and Pharmacology, University of South China, Hengyang 421001, China; [email protected] 2 Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, China 3 Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, College of Pharmaceutical Science, Soochow University, Suzhou 215123, China * Correspondence: [email protected]; Tel./Fax: +86-512-65882071 Received: 23 December 2017; Accepted: 24 February 2018; Published: 28 February 2018 Abstract: Naja naja atra venom (NNAV) is composed of various proteins, peptides, and enzymes with different biological and pharmacological functions. A number of previous studies have reported that NNAV exerts potent analgesic effects on various animal models of pain. The clinical studies using whole venom or active components have confirmed that NNAV is an effective and safe medicine for treatment of chronic pain. Furthermore, recent studies have demonstrated that NNAV has anti-inflammatory and immune regulatory actions in vitro and in vivo. In this review article, we summarize recent studies of NNAV and its components on inflammation and immunity. The main new findings in NNAV research show that it may enhance innate and humoral immune responses while suppressing T lymphocytes-mediated cellular immunity, thus suggesting that NNAV and its active components may have therapeutic values in the treatment of inflammatory and autoimmune diseases.
    [Show full text]
  • Rope Parasite” the Rope Parasite Parasites: Nearly Every AuSC Child I Ever Treated Proved to Carry a Significant Parasite Burden
    Au#sm: 2015 Dietrich Klinghardt MD, PhD Infec4ons and Infestaons Chronic Infecons, Infesta#ons and ASD Infec4ons affect us in 3 ways: 1. Immune reac,on against the microbes or their metabolic products Treatment: low dose immunotherapy (LDI, LDA, EPD) 2. Effects of their secreted endo- and exotoxins and metabolic waste Treatment: colon hydrotherapy, sauna, intes4nal binders (Enterosgel, MicroSilica, chlorella, zeolite), detoxificaon with herbs and medical drugs, ac4vaon of detox pathways by solving underlying blocKages (methylaon, etc.) 3. Compe,,on for our micronutrients Treatment: decrease microbial load, consider vitamin/mineral protocol Lyme, Toxins and Epigene#cs • In 2000 I examined 10 au4s4c children with no Known history of Lyme disease (age 3-10), with the IgeneX Western Blot test – aer successful treatment. 5 children were IgM posi4ve, 3 children IgG, 2 children were negave. That is 80% of the children had clinical Lyme disease, none the history of a 4cK bite! • Why is it taking so long for au4sm-literate prac44oners to embrace the fact, that many au4s4c children have contracted Lyme or several co-infec4ons in the womb from an oVen asymptomac mother? Why not become Lyme literate also? • Infec4ons can be treated without the use of an4bio4cs, using liposomal ozonated essen4al oils, herbs, ozone, Rife devices, PEMF, colloidal silver, regular s.c injecons of artesunate, the Klinghardt co-infec4on cocKtail and more. • Symptomac infec4ons and infestaons are almost always the result of a high body burden of glyphosate, mercury and aluminum - against the bacKdrop of epigene4c injuries (epimutaons) suffered in the womb or from our ancestors( trauma, vaccine adjuvants, worK place related lead, aluminum, herbicides etc., electromagne4c radiaon exposures etc.) • Most symptoms are caused by a confused upregulated immune system (molecular mimicry) Toxins from a toxic environment enter our system through damaged boundaries and membranes (gut barrier, blood brain barrier, damaged endothelium, etc.).
    [Show full text]
  • Amphiphilic B-Sheet Cobra Cardiotoxin Targets Mitochondria and Disrupts Its Network
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector FEBS 29626 FEBS Letters 579 (2005) 3169–3174 Amphiphilic b-sheet cobra cardiotoxin targets mitochondria and disrupts its network Chia-Hui Wang, Wen-guey Wu* Department of Life Sciences, Institute of Bioinformatics and Structural Biology, National Tsinghua University, 101, Section 2, Kuang Fu Road, Hsinchu 30013, Taiwan Received 29 March 2005; revised 2 May 2005; accepted 2 May 2005 Available online 23 May 2005 Edited by Maurice Montal brane is likely to be involved in the CTX-induced perturbation Abstract Recent advance in understanding the role of toxin proteins in controlling cell death has revealed that pro-apoptotic of cytosolic calcium homeostasis and hypercontracture in rat viral proteins targeting mitochondria contain amphiphilic a-heli- ventricular myocytes [5,10]; however, evidence indicating ces with pore-forming properties. Herein, we describe that the that CTX may target intracellular organelle within the cell is pore-forming amphiphilic b-sheet cardiotoxins (or cytotoxins, lacking. CTXs) from Taiwan cobra (Naja atra) also target mitochondrial A large number of protein toxins from bacteria and virus membrane after internalization and act synergistically with have been extensively studied in order to understand their CTX-induced cytosolic calcium increase to disrupt mitochondria mechanism of action as well as of intracellular membrane network. It is suggested that CTX-induced fragmentation of trafficking [11–13]. For instance, cholera toxin and related mitochondria play a role in controlling CTX-induced necrosis AB5-subunit bacterial toxin have been shown to follow a of myocytes and cause severe tissue necrosis in the victims.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0191272 A1 Stemmer Et Al
    US 200701.91272A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0191272 A1 Stemmer et al. (43) Pub. Date: Aug. 16, 2007 (54) PROTEINACEOUS PHARMACEUTICALS Publication Classification AND USES THEREOF (76) Inventors: Willem P.C. Stemmer, Los Gatos, CA (51) Int. Cl. (US); Volker Schellenberger, Palo A6II 38/16 (2006.01) Alto, CA (US); Martin Bader, C40B 40/08 (2006.01) Mountain View, CA (US); Michael C40B 40/10 (2006.01) Scholle, Mountain View, CA (US) C07K I4/47 (2006.01) (52) U.S. Cl. ................. 514/12: 435/7.1: 435/6; 530/324 Correspondence Address: WILSON SONSN GOODRCH & ROSAT 650 PAGE MILL ROAD (57) ABSTRACT PALO ALTO, CA 94304-1050 (US) (21) Appl. No.: 11/528,927 The present invention provides cysteine-containing scaf folds and/or proteins, expression vectors, host cell and (22) Filed: Sep. 27, 2006 display systems harboring and/or expressing such cysteine containing products. The present invention also provides Related U.S. Application Data methods of designing libraries of Such products, methods of (60) Provisional application No. 60/721,270, filed on Sep. screening Such libraries to yield entities exhibiting binding 27, 2005. Provisional application No. 60/721,188, specificities towards a target molecule. Further provided by filed on Sep. 27, 2005. Provisional application No. the invention are pharmaceutical compositions comprising 60/743,622, filed on Mar. 21, 2006. the cysteine-containing products of the present invention. Patent Application Publication Aug. 16, 2007 Sheet 1 of 46 US 2007/0191272 A1 Takara togra: Patent Application Publication Aug. 16, 2007 Sheet 2 of 46 US 2007/0191272 A1 FIG.
    [Show full text]
  • (73) Assignee If Its of the Sawengy
    US 2008O131500A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0131500 A1 CHANG (43) Pub. Date: Jun. 5, 2008 (54) METHODS AND COMPOSITIONS FOR AOIP I/00 (2006.01) RAPID INACTIVATION OF PROTEINS A6II 47/02 (2006.01) A 6LX 39/395 (2006.01) (75) Inventor: ROWEN.J.-Y. CHANG, Houston, C07K I4/00 (2006.01) TX (US) AOIN 25/00 (2006.01) (52) U.S. Cl. ......... 424/451; 530/410; 530/408; 530/402; Correspondence Address: 530/409:514/769; 424/130.1; 424/45 FULBRIGHT & UAWORSK L.L.P. 600 CONGRESSAVE., SUITE 2400 (57) ABSTRACT AUSTIN, TX 78701 Disclosed are methods of inactivating a protein, Such as leavi disulfide bond of tein, that invol tacti (73) Assignee niversityif of Texasits Systemof the ideSAWENGy ion, wherein the pH of the composition is about 10.0 to about 14.0. Also disclosed are methods of treating or prevent (21) Appl. No.: 11/566,595 ing a disease in a subject, such as a toxin-related disease or a 1-1. prion-related disease, that involve contacting a subject with a (22) Filed: Dec. 4, 2006 pharmaceutically effective amount of a reducing agent, a O O denaturant, and a hydroxide ion, wherein the pH of the com Publication Classification position is about 9.0 to about 14.0. Also disclosed are com (51) Int. Cl. positions that include a reducing agent, a denaturant, and a A6 IK 9/48 (2006.01) hydroxide ion, wherein the pH of the composition is about 9.0 A6IP 25/28 (2006.01) to about 14.0.
    [Show full text]
  • Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 203639, 19 pages http://dx.doi.org/10.1155/2014/203639 Review Article Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy Leonardo A. Calderon,1 Juliana C. Sobrinho,1 Kayena D. Zaqueo,1 Andrea A. de Moura,1 Amy N. Grabner,1 Maurício V. Mazzi,2 Silvana Marcussi,3 Auro Nomizo,4 CarlaF.C.Fernandes,1 Juliana P. Zuliani,1 Bruna M. A. Carvalho,5 Saulo L. da Silva,5 Rodrigo G. Stábeli,1 and Andreimar M. Soares1 1 Centro de Estudos de Biomoleculas´ Aplicadas aSa` ude,´ CEBio, Fundac¸ao˜ Oswaldo Cruz, Fiocruz Rondoniaˆ e Departamento de Medicina, Universidade Federal de Rondonia,ˆ UNIR, Porto Velho, RO, Brazil 2 Fundac¸ao˜ Herm´ınio Ometto, UNIARARAS, Nucleo´ de Cienciasˆ da Saude-NUCISA,´ 13607-339 Araras, SP, Brazil 3 Departamento de Qu´ımica, Universidade Federal de Lavras, UFLA, 37200-000 Lavras, MG, Brazil 4 Departamento de Analises´ Cl´ınicas, Toxicologicas´ e Bromatologicas,´ Faculdade de Cienciasˆ Farmaceuticasˆ de Ribeirao˜ Preto, Universidade de Sao˜ Paulo, USP, Ribeirao˜ Preto, SP, Brazil 5 Departamento de Qu´ımica, Biotecnologia e Engenharia de Bioprocessos, Universidade Federal de Sao˜ Joao˜ del Rei, UFSJ, Campus Alto paraopeba, Ouro Branco, MG, Brazil Correspondence should be addressed to Andreimar M. Soares; [email protected] Received 20 September 2013; Revised 7 December 2013; Accepted 8 December 2013; Published 13 February 2014 Academic Editor: Fernando Albericio Copyright © 2014 Leonardo A. Calderon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Privileged Frameworks from Snake Venom
    Cell. Mol. Life Sci. (2015) 72:1939–1958 DOI 10.1007/s00018-015-1844-z Cellular and Molecular Life Sciences REVIEW Privileged frameworks from snake venom T. A. Reeks • B. G. Fry • P. F. Alewood Received: 17 December 2014 / Revised: 22 January 2015 / Accepted: 26 January 2015 / Published online: 19 February 2015 Ó Springer Basel 2015 Abstract Venom as a form of chemical prey capture is a Introduction key innovation that has underpinned the explosive ra- diation of the advanced snakes (Caenophidia). Small While venom in reptiles had a single, early evolution [1, 2], venom proteins are often rich in disulfide bonds thus it is at the base of the advanced snakes that it truly became facilitating stable molecular scaffolds that present key a key evolutionary innovation that underpinned the ex- functional residues on the protein surface. New toxin types plosive radiation of this lineage [3]. Snake venom is a are initially developed through the venom gland over-ex- complex mixture of enzymes, proteins and peptides. Many pression of normal body proteins, their subsequent gene of these toxin families have stable molecular scaffolds duplication and diversification that leads to neofunction- (Table 1). The toxins within the venom are a result of gene alisation as random mutations modify their structure and duplication of proteins or peptides typically used elsewhere function. This process has led to preferentially selected in the body, with the copy being selectively expressed in (privileged) cysteine-rich scaffolds that enable the snake to the venom gland [4]. These genes are often amplified into build arrays of toxins many of which may lead to multi-gene families with diverse neofunctionalisation fol- therapeutic products and research tools.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,846.445 B2 Schellenberger Et Al
    USOO7846445B2 (12) United States Patent (10) Patent No.: US 7,846.445 B2 Schellenberger et al. (45) Date of Patent: Dec. 7, 2010 (54) METHODS FOR PRODUCTION OF 5,176,502 A 1/1993 Sanderson et al. UNSTRUCTURED RECOMBINANT 5, 186,938 A 2/1993 Sablotsky et al. POLYMERS AND USES THEREOF 5,215,680 A 6/1993 D'arrigo 5,223,409 A 6/1993 Ladner et al. (75) Inventors: Volker Schellenberger, Palo Alto, CA 5,270,176 A * 12/1993 Dorschug et al. .......... 435/69.7 (US); Willem P. Stemmer, Los Gatos, 5,298,022 A 3, 1994 Bernardi CA (US); Chia-wei Wang, Santa Clara, 5,318.540 A 6, 1994 Athayde et al. CA (US); Michael D. Schole, Mountain 5,407,609 A 4/1995 Tice et al. View, CA (US); Mikhail Popkov, San 2. 3. E. 1 Diego, CA (US); Nathaniel C. Gordon, - - I oiszwillo et al. Campbell, CA (US); Andreas Crameri, 5,573,776 A 11, 1996 Harrison et al. Los Altos Hills, CA (US) 5,578,709 A 11/1996 WoiSZwillo s 5,599.907 A * 2/1997 Anderson et al. ........... 530,385 5,660,848 A 8, 1997 Moo-Youn (73) Assignee: suioperating, Inc., Mountain 5,756,115 A 5, 1998 NSW et al. iew, CA (US) 5,874,104 A 2/1999 Adler-moore et al. 5,916,588 A 6, 1999 P tal. (*) Notice: Subject to any disclaimer, the term of this 5,942,252 A 8, 1999 p al patent is extended or adjusted under 35 5,965,156 A 10, 1999 Profitt et al.
    [Show full text]
  • Toxines Et Fonctions Cholinergiques Neuronales Et Non Neuronales
    Collection Rencontres en toxinologie © P. Marchot & J.-L. Boudier TTooxxiinneess eett ffoonnccttiioonnss cchhoolliinneerrggiiqquueess nneeuurroonnaalleess eett nnoonn nneeuurroonnaalleess Comité d’édition : Evelyne BENOIT, Françoise GOUDEY-PERRIERE, Pascale MARCHOT et Denis SERVENT Société Française pour l'Etude des Toxines Illustrations de couverture : En haut : Vue en microscopie électronique des synapses neuromusculaires du muscle triangulaire de sternum de souris (grossissement de 13 333 fois). Les pelotes noires sont générées par des molécules d’alpha-neurotoxine « à trois doigts », isolée d’un venin de cobra et radioiodée, fixées aux récepteurs nicotiniques de l’acétylcholine associés aux membranes post-synaptiques. (Copyright Pascale Marchot et Jean-Louis Boudier) En bas : Vue cristallographique du complexe de haute affinité formé entre (en jaune) cinq exemplaires d’une alpha- neurotoxine « à trois doigts », isolée d’un venin de cobra, et (en bleu) l’acetylcholine binding protein, protéine homopentamérique de mollusque aquatique et équivalent soluble du domaine extracellulaire de fixation des ligands du récepteur nicotinique de l’acétylcholine. (Copyright Pascale Marchot et Yves Bourne) Près de vingt ans de travaux menés par de nombreuses équipes au plan international relient ces deux images. Collection Rencontres en toxinologie La collection « Rencontres en toxinologie » est publiée à l’occasion des Colloques annuels « Rencontres en toxinologie » organisés par la Société Française pour l’Etude des Toxines (SFET). Les ouvrages parus de 2001 à 2007 ont été édités par Elsevier (Paris, France), puis par la Librairie Lavoisier (Cachan, France). A partir de 2008, ils seront édités par la SFET et diffusés sur le site http://www.sfet.asso.fr, en libre accès pour les auteurs et les lecteurs.
    [Show full text]
  • Information Resources on the South American Camelids: Llamas, Alpacas, Guanacos, and Vicunas 2004-2008
    NATIONAL AGRICULTURAL LIBRARY ARCHIVED FILE Archived files are provided for reference purposes only. This file was current when produced, but is no longer maintained and may now be outdated. Content may not appear in full or in its original format. All links external to the document have been deactivated. For additional information, see http://pubs.nal.usda.gov. United States Department of Information Resources on the Agriculture Agricultural Research South American Camelids: Service National Agricultural Llamas, Alpacas, Guanacos, Library Animal Welfare Information Center and Vicunas 2004-2008 AWIC Resource Series No. 12, Revised 2009 AWIC Resource Series No. 12, Revised 2009 United States Information Resources on the Department of Agriculture South American Agricultural Research Service Camelids: Llamas, National Agricultural Alpacas, Guanacos, and Library Animal Welfare Vicunas 2004-2008 Information Center AWIC Resource Series No. 12, Revised 2009 Compiled by: Jean A. Larson, M.S. Animal Welfare Information Center National Agricultural Library U.S. Department of Agriculture Beltsville, Maryland 20705 E-mail: [email protected] Web site: http://awic.nal.usda.gov Available online: http://www.nal.usda.gov/awic/pubs/Camelids/camelids.shtml Disclaimers Te U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and activities on the basis of race, color, national origin, age, disability, and where applicable, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or a part of an individual’s income is derived from any public assistance program. (Not all prohibited bases apply to all programs.) Persons with disabilities who require alternative means for communication of program information (Braille, large print, audiotape, etc.) should contact USDA’s TARGET Center at (202) 720-2600 (voice and TDD).
    [Show full text]
  • Neural Computation for Rehabilitation Animal Toxins and Their Advantages in Biotechnology and Pharmacology
    BioMed Research International Animal Toxins and Their Advantages in Biotechnology and Pharmacology Guest Editors: S. L. Da Silva, E. G. Rowan, F. Albericio, R. G. Stábeli, NeuralL. A. Calderon, Computation and A. M. Soares for Rehabilitation Animal Toxins and Their Advantages in Biotechnology and Pharmacology BioMed Research International Animal Toxins and Their Advantages in Biotechnology and Pharmacology Guest Editors: S. L. Da Silva, E. G. Rowan, F. Albericio, R. G. Stabeli,´ L. A. Calderon, and A. M. Soares Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “BioMed Research International.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Contents Animal Toxins and Their Advantages in Biotechnology and Pharmacology,S.L.DaSilva,E.G.Rowan, F. Albericio, R. G. Stabeli,´ L. A. Calderon, and A. M. Soares Volume 2014, Article ID 951561, 2 pages Alkylation of Histidine Residues of Bothrops jararacussu Venom Proteins and Isolated Phospholipases A2: A Biotechnological Tool to Improve the Production of Antibodies,C.L.S.Guimaraes,˜ S. H. Andriao-Escarso,L.S.Moreira-Dill,B.M.A.Carvalho,D.P.Marchi-Salvador,N.A.Santos-Filho,˜ C. A. H. Fernandes, M. R. M. Fontes, J. R. Giglio, B. Barraviera, J. P. Zuliani, C. F. C. Fernandes, L. A. Calderon,´ R. G. Stabeli,´ F. Albericio, S. L. da Silva, and A. M. Soares Volume 2014, Article ID 981923, 12 pages Biochemical and Functional Characterization of Parawixia bistriata Spider Venom with Potential Proteolytic and Larvicidal Activities, Gizeli S.
    [Show full text]
  • Wo 2007/038619 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 5 April 2007 (05.04.2007) WO 2007/038619 A2 (51) International Patent Classification: (74) Agents: WONG, Karen, K. et al.; WILSON SONSINI C40B 40/10 (2006.01) GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US). (21) International Application Number: PCT/US2006/037713 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, 27 September 2006 (27.09.2006) CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, (25) Filing Language: English KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (26) Publication Language: English NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW 60/721,270 27 September 2005 (27.09.2005) US 60/721,188 27 September 2005 (27.09.2005) US (84) Designated States (unless otherwise indicated, for every 60/743,622 21 March 2006 (2 1.03.2006) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AMU- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), NIX, INC.
    [Show full text]